Biora Therapeutics, Inc. (BIORQ)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jun 1, 2026, 4:00 PM EST
Market Cap442.00 -100.0%
Revenue (ttm)892.00K +4,855.6%
Net Income-31.54M
EPS-10.46
Shares Out 4.42M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,002
Open0.0001
Previous Close0.0001
Day's Range0.0001 - 0.0001
52-Week Range0.000001 - 0.3400
Beta158.77
Analystsn/a
Price Targetn/a
Earnings Daten/a

About Biora Therapeutics

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 58
Stock Exchange OTCMKTS
Ticker Symbol BIORQ
Full Company Profile

Financial Performance

In 2023, Biora Therapeutics's revenue was $4,000, a decrease of -98.69% compared to the previous year's $305,000. Losses were -$124.12 million, 225.3% more than in 2022.

Financial Statements

News

Biora Therapeutics Quarterly report: Q3 2024

Biora Therapeutics has published its Q3 2024 quarterly earnings report on November 14, 2024.

1 year ago - Filings

Biora Therapeutics Earnings release: Q3 2024

Biora Therapeutics released its Q3 2024 earnings on November 14, 2024, summarizing the period's financial results.

1 year ago - Filings

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Testing in advanced animal model planned in Q4 f or smaller, 00-size BioJet device with largest capacity of any ingestible injectable

1 year ago - GlobeNewsWire

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide...

1 year ago - GlobeNewsWire

Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreemen...

1 year ago - GlobeNewsWire

Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting

Expanded collaborations to support rapid testing in advanced animal models in Q4 2024 Expanded collaborations to support rapid testing in advanced animal models in Q4 2024

1 year ago - GlobeNewsWire

Biora Therapeutics Proxy statement: Proxy Filing

Biora Therapeutics filed a proxy statement on October 23, 2024, providing details for shareholder voting and corporate governance matters.

1 year ago - Filings

Biora Therapeutics Proxy statement: Proxy Filing

Biora Therapeutics filed a proxy statement on October 11, 2024, providing details for shareholder voting and corporate governance matters.

1 year ago - Filings

Biora Therapeutics Proxy statement: Proxy Filing

Biora Therapeutics filed a proxy statement on September 16, 2024, providing details for shareholder voting and corporate governance matters.

1 year ago - Filings

Biora Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Two innovative drug-device platforms were highlighted: NaviCap, which showed strong phase I results for targeted ulcerative colitis therapy, and BioJet, advancing needle-free biologic delivery with active pharma partnering discussions. Both programs are positioned for significant near-term milestones.

1 year ago - Transcripts

Biora Therapeutics Proxy statement: Proxy Filing

Biora Therapeutics filed a proxy statement on September 3, 2024, providing details for shareholder voting and corporate governance matters.

1 year ago - Filings

Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in ...

1 year ago - GlobeNewsWire

Biora Therapeutics Registration statement: Registration Filing

Biora Therapeutics filed a registration statement on August 23, 2024, providing details about a securities offering with the SEC.

1 year ago - Filings

Biora Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Two proprietary platforms enable targeted and systemic oral drug delivery, with NaviCap showing strong phase I results in UC and BioJet advancing through major pharma collaborations. Next steps include a larger UC trial and anticipated BioJet partnerships.

1 year ago - Transcripts

Biora Therapeutics Earnings Call Transcript: Q2 2024

Q2 2024 saw successful Phase 1 results for BT-600, strong progress with BioJet, and a $16M capital raise. BioJet achieved ~40% bioavailability, and partnership talks with major pharma are nearing completion. Clinical trials and manufacturing scale-up are on track.

1 year ago - Transcripts

Biora Therapeutics Quarterly report: Q2 2024

Biora Therapeutics has published its Q2 2024 quarterly earnings report on August 12, 2024.

1 year ago - Filings

Biora Therapeutics Earnings release: Q2 2024

Biora Therapeutics released its Q2 2024 earnings on August 12, 2024, summarizing the period's financial results.

1 year ago - Filings

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan

1 year ago - GlobeNewsWire

Biora Therapeutics Announces Funding Agreement with Existing Investors

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced the signing of financing agreements with its...

1 year ago - GlobeNewsWire

Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide...

1 year ago - GlobeNewsWire

Biora Therapeutics Transcript: Study Update

Phase I results for BT-600 using the NaviCap platform showed precise, pancolonic delivery of tofacitinib with significantly reduced systemic exposure and strong safety in healthy volunteers. These findings support further clinical development in ulcerative colitis patients.

2 years ago - Transcripts

Biora Therapeutics Press release: Study Update

Biora Therapeutics issued a press release on July 17, 2024, disclosing material business information to investors.

2 years ago - Filings

Biora Therapeutics Slides: Study Update

Biora Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 17, 2024.

2 years ago - Filings

Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical dat...

2 years ago - GlobeNewsWire

Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024

Four device performance studies demonstrate the NaviCap platform's ability to deliver therapeutics directly to the colon under variable GI conditions.

2 years ago - GlobeNewsWire